Coronary Revascularization & Timing of Treatment - Considering the Evidence, Building a Research Plan

May 8, 2017 - 12:00pm to 1:00pm
700-828 W. 10 Ave., VGH Research Pavilion
Sean Hardiman

Patients who have multi-vessel coronary artery disease that is refractory to medical therapies have two options available to them to reduce their risk of mortality: coronary artery bypass graft (CABG) surgery, or percutaneous coronary intervention (PCI), also known as angioplasty.  Patients who have CABG generally have better survival than PCI, but CABG often requires the patient to wait for their surgery.  PCI, on the other hand, is generally immediately available.  It is unknown whether the therapeutic benefits of CABG extend to times when patients must wait beyond recommended waiting times, or whether PCI is the preferred strategy in this situations.  At the conclusion of this talk, participants will understand the key differences between the therapeutic approaches to coronary revascularization, the evidence base for each, and appreciate the health services system configurations that lead to variable access.  A research plan to respond to this question will also be presented.